X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1081) 1081
Book Review (190) 190
Publication (54) 54
Book Chapter (5) 5
Conference Proceeding (3) 3
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (905) 905
humans (865) 865
esomeprazole (607) 607
male (604) 604
female (567) 567
omeprazole (455) 455
middle aged (453) 453
proton pump inhibitors (447) 447
adult (437) 437
gastroenterology & hepatology (420) 420
pharmacology & pharmacy (368) 368
esomeprazole - administration & dosage (353) 353
treatment outcome (335) 335
aged (307) 307
gastroesophageal reflux - drug therapy (235) 235
lansoprazole (227) 227
esomeprazole - therapeutic use (219) 219
proton pump inhibitors - administration & dosage (215) 215
anti-ulcer agents - administration & dosage (214) 214
proton pump inhibitors - therapeutic use (204) 204
gastroesophageal reflux (171) 171
gastroesophageal-reflux disease (169) 169
drug therapy, combination (167) 167
anti-ulcer agents - therapeutic use (163) 163
rabeprazole (156) 156
proton pump inhibitor (152) 152
pharmacokinetics (149) 149
drug administration schedule (148) 148
dose-response relationship, drug (143) 143
helicobacter infections - drug therapy (140) 140
double-blind method (137) 137
esomeprazole - adverse effects (137) 137
helicobacter pylori (137) 137
adolescent (132) 132
pantoprazole (131) 131
therapy (129) 129
management (125) 125
medicine & public health (121) 121
young adult (121) 121
prospective studies (116) 116
proton pump inhibitors - adverse effects (116) 116
double-blind (111) 111
erosive esophagitis (110) 110
administration, oral (109) 109
care and treatment (109) 109
aged, 80 and over (105) 105
efficacy (105) 105
gastroesophageal reflux disease (102) 102
internal medicine (100) 100
hydrogen-ion concentration (99) 99
drug therapy (98) 98
dosage and administration (97) 97
cross-over studies (95) 95
abridged index medicus (91) 91
medicine, general & internal (91) 91
omeprazole - administration & dosage (89) 89
drug interactions (88) 88
esophagitis (86) 86
clinical trials (85) 85
time factors (85) 85
pharmacology/toxicology (84) 84
symptoms (83) 83
risk factors (80) 80
esomeprazole - pharmacology (77) 77
anti-ulcer agents - adverse effects (76) 76
proton pump inhibitors - pharmacology (75) 75
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (74) 74
omeprazole - therapeutic use (74) 74
metaanalysis (73) 73
health aspects (72) 72
infection (72) 72
2-pyridinylmethylsulfinylbenzimidazoles (71) 71
animals (70) 70
helicobacter pylori - drug effects (70) 70
anti-bacterial agents - therapeutic use (68) 68
esomeprazole - pharmacokinetics (68) 68
research (67) 67
eradication (66) 66
gastric acid - secretion (66) 66
risk (66) 66
anti-bacterial agents - administration & dosage (65) 65
amoxicillin - administration & dosage (64) 64
ulcers (64) 64
prevention (63) 63
follow-up studies (62) 62
gerd (62) 62
anti-ulcer agents - pharmacology (61) 61
aspirin (61) 61
heartburn (61) 61
intragastric ph (61) 61
disease (60) 60
analysis (59) 59
severity of illness index (56) 56
diagnosis (55) 55
esomeprazole 40 mg (55) 55
proton-pump inhibitors (55) 55
gastroenterology (54) 54
pharmacotherapy (54) 54
proton pump inhibitors - pharmacokinetics (54) 54
clarithromycin (52) 52
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1049) 1049
German (7) 7
Russian (7) 7
French (6) 6
Spanish (5) 5
Korean (4) 4
Chinese (3) 3
Swedish (3) 3
Bulgarian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10058, pp. 2355 - 2365
Summary Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter... 
Internal Medicine | CLARITHROMYCIN | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EFFICACY | GASTRIC-CANCER | RESISTANCE | SEQUENTIAL THERAPY | INFECTION | ERADICATION | METRONIDAZOLE | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Antacids - therapeutic use | Anti-Bacterial Agents - therapeutic use | Proton Pump Inhibitors - administration & dosage | Metronidazole - therapeutic use | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Organometallic Compounds - therapeutic use | Female | Urea - metabolism | Amoxicillin - administration & dosage | Lansoprazole - administration & dosage | Drug Administration Schedule | Metronidazole - administration & dosage | Breath Tests | Tetracycline - therapeutic use | Clarithromycin - therapeutic use | Proton Pump Inhibitors - therapeutic use | Amoxicillin - therapeutic use | Taiwan | Drug Therapy, Combination - statistics & numerical data | Lansoprazole - therapeutic use | Antacids - administration & dosage | Anti-Bacterial Agents - administration & dosage | Tetracycline - administration & dosage | Organometallic Compounds - administration & dosage | Clinical trials | Medical colleges | Helicobacter infections | Care and treatment | Helicobacter pylori | Antiulcer drugs | Analysis | Bacteria | Bacterial infections | Antibiotics | Drug resistance | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 2016, Volume 32, pp. 84 - 90
Abstract Background Currently only a few studies compare sequential and concomitant non-bismuth Helicobacter pylori therapies referring to high antibiotic... 
Internal Medicine | H. pylori treatment | Sequential treatment | First line | Concomitant treatment | Metronidazole resistance | Clarithromycin resistance | 14-DAY TRIPLE | 1ST-LINE TREATMENT | MULTICENTER | METAANALYSIS | REGIMEN | STANDARD TRIPLE THERAPY | RATES | MEDICINE, GENERAL & INTERNAL | INFECTION | HYBRID THERAPY | DURATION | Esomeprazole - administration & dosage | Humans | Middle Aged | Carbon Isotopes | Drug Resistance, Bacterial | Male | Helicobacter Infections - pathology | Helicobacter pylori | Peptic Ulcer - microbiology | Proton Pump Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Adult | Female | Helicobacter Infections - metabolism | Urea - metabolism | Amoxicillin - administration & dosage | Drug Therapy, Combination | Dyspepsia - drug therapy | Metronidazole - administration & dosage | Breath Tests | Dyspepsia - microbiology | Pyloric Antrum - pathology | Biopsy | Aged | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Clinical trials | Drug resistance in microorganisms | Clarithromycin | Index Medicus | Helicobacter Infections/drug therapy | Peptic Ulcer/drug therapy | Proton Pump Inhibitors/administration & dosage | Helicobacter Infections/pathology | Peptic Ulcer/microbiology | Tissues and Organs | Life Sciences | Esomeprazole/administration & dosage | Hépatology and Gastroenterology | Pyloric Antrum/pathology | Anti-Bacterial Agents/administration & dosage | Dyspepsia/microbiology | Helicobacter Infections/metabolism | Bacteriology | Clarithromycin/administration & dosage | Urea/metabolism | Metronidazole/administration & dosage | Microbiology and Parasitology | Human health and pathology | Amoxicillin/administration & dosage | Dyspepsia/drug therapy
Journal Article
CMAJ, ISSN 0820-3946, 11/2011, Volume 183, Issue 16, pp. 1835 - 1843
Background: Patients prescribed antiplatelet treatment to prevent recurrent acute myocardial infarction are often also given a selective serotonin reuptake... 
DEPRESSION | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | ANTIDEPRESSANTS | CLOPIDOGREL | EVENTS | PROGNOSIS | DRUGS | ELDERLY-PATIENTS | ASPIRIN | Age Factors | Anemia - epidemiology | Angioplasty | Humans | Middle Aged | Citalopram - adverse effects | Male | Risk | Secondary Prevention | Sertraline - adverse effects | Peptic Ulcer - epidemiology | Adrenal Cortex Hormones - therapeutic use | Renal Insufficiency - epidemiology | Aspirin - administration & dosage | Paroxetine - adverse effects | Paroxetine - administration & dosage | Fluvoxamine - administration & dosage | Canada - epidemiology | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Retrospective Studies | Drug Therapy, Combination | Heart Failure - epidemiology | Fluoxetine - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Hypoglycemic Agents - therapeutic use | Hemorrhage - epidemiology | Risk Factors | Serotonin Uptake Inhibitors - adverse effects | Anticoagulants - therapeutic use | Antihypertensive Agents - therapeutic use | Fluvoxamine - adverse effects | Ticlopidine - analogs & derivatives | Citalopram - administration & dosage | Sertraline - administration & dosage | Serotonin Uptake Inhibitors - administration & dosage | Fluoxetine - administration & dosage | Sex Factors | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Neoplasms - epidemiology | Cohort Studies | Aggregation | Complications and side effects | Blood platelets | Patient outcomes | Serotonin uptake inhibitors | Dosage and administration | Drug therapy | Hemorrhage | Heart attack | Risk factors | Studies | Side effects | Heart attacks | Inhibitor drugs | Index Medicus | Abridged Index Medicus | Research
Journal Article
Gastroenterology, ISSN 0016-5085, 10/2018, Volume 155, Issue 4, pp. 1109 - 1119
BACKGROUND & AIMS: We aimed to compare the efficacy of genotypic resistance-guided therapy vs empirical therapy for eradication of refractory Helicobacter... 
Third-Line | Susceptibility Testing | 23S rRNA | Gyrase A | 1ST-LINE TREATMENT | MULTICENTER | METAANALYSIS | RANDOMIZED-TRIAL | SEQUENTIAL THERAPY | OPEN-LABEL | LEVOFLOXACIN | 3RD-LINE TREATMENT | TRIPLE THERAPY | ERADICATION | GASTROENTEROLOGY & HEPATOLOGY | Predictive Value of Tests | Esomeprazole - administration & dosage | Humans | Middle Aged | Helicobacter pylori - genetics | Helicobacter pylori - pathogenicity | Helicobacter pylori - drug effects | Male | Doxycycline - administration & dosage | Proton Pump Inhibitors - administration & dosage | Time Factors | Clinical Decision-Making | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Adult | Bacteriological Techniques | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Drug Resistance, Bacterial - genetics | Drug Therapy, Combination | Levofloxacin - administration & dosage | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Metronidazole - administration & dosage | Breath Tests | Genotype | Treatment Outcome | Taiwan | Aged | Anti-Bacterial Agents - administration & dosage | Tetracycline - administration & dosage | Helicobacter Infections - microbiology | Helicobacter infections | Care and treatment | Helicobacter pylori | Health aspects | Analysis | Index Medicus | Abridged Index Medicus
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 04/2015, Volume 41, Issue 8, pp. 768 - 775
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2016, Volume 117, Issue 3, pp. 366 - 368
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2013, Volume 71, Issue 6, pp. 1635 - 1643
The metabolism of pazopanib is primarily mediated by CYP3A4. The solubility of pazopanib is pH-dependent, and an elevated gastric pH may decrease its... 
Medicine & Public Health | Ketoconazole | Esomeprazole | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | CYP3A4 | Pazopanib | RABEPRAZOLE | HEALTHY-SUBJECTS | 24-H | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | INHIBITOR | PHASE-I | DRUG-INTERACTION | Neoplasms - metabolism | Proton Pump Inhibitors - pharmacology | Esomeprazole - administration & dosage | Cytochrome P-450 CYP3A | Ketoconazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Esomeprazole - pharmacology | Male | Ketoconazole - pharmacology | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Angiogenesis Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Pyrimidines - administration & dosage | Angiogenesis Inhibitors - pharmacokinetics | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Cytochrome P-450 CYP3A Inhibitors | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Sulfonamides - adverse effects | Aged | Ketoconazole - adverse effects | Sulfonamides - administration & dosage | Care and treatment | Metabolites | Analysis | Cytochrome P-450 | Tumors | Antiulcer drugs | Index Medicus
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 03/2019, Volume 25, Issue 5, pp. 1479 - 1485
Purpose: Pazopanib is active in soft-tissue sarcoma (STS). Because pazopanib absorption is pH-dependent, coadministration with gastric acid-suppressive (GAS)... 
ESOMEPRAZOLE | EFFICACY | PHARMACOKINETICS | ONCOLOGY | TYROSINE-KINASE INHIBITORS | OMEPRAZOLE | PROTON PUMP INHIBITORS | ABSORPTION | ERLOTINIB | EXPOSURE
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 1, pp. 55 - 61.e1
Journal Article
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 05/2016, Volume 43, Issue 10, pp. 1048 - 1059
Journal Article